HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,869,545 | +17.3% | 101,297 | +10.7% | 0.02% | +23.1% |
| Q2 2023 | $3,299,251 | +18.2% | 91,468 | +25.2% | 0.01% | +8.3% |
| Q1 2023 | $2,790,925 | -67.8% | 73,080 | -52.0% | 0.01% | -71.4% |
| Q4 2022 | $8,670,877 | +21.1% | 152,388 | -15.9% | 0.04% | +13.5% |
| Q3 2022 | $7,163,000 | -16.8% | 181,153 | -7.4% | 0.04% | -11.9% |
| Q2 2022 | $8,607,000 | +11.3% | 195,613 | +0.9% | 0.04% | +40.0% |
| Q1 2022 | $7,731,000 | -0.8% | 193,869 | 0.0% | 0.03% | +3.4% |
| Q4 2021 | $7,795,000 | +177.8% | 193,869 | +181.0% | 0.03% | +123.1% |
| Q3 2021 | $2,806,000 | +13.6% | 68,989 | +26.8% | 0.01% | +18.2% |
| Q2 2021 | $2,471,000 | -14.6% | 54,424 | -21.6% | 0.01% | -15.4% |
| Q1 2021 | $2,895,000 | -40.4% | 69,445 | -38.9% | 0.01% | -38.1% |
| Q4 2020 | $4,854,000 | +65.1% | 113,661 | +1.6% | 0.02% | +50.0% |
| Q3 2020 | $2,940,000 | -23.6% | 111,881 | -22.0% | 0.01% | -26.3% |
| Q2 2020 | $3,847,000 | +50.6% | 143,477 | +1.0% | 0.02% | +18.8% |
| Q1 2020 | $2,555,000 | +90.2% | 142,011 | +87.4% | 0.02% | +128.6% |
| Q4 2019 | $1,343,000 | -42.7% | 75,768 | -49.8% | 0.01% | -46.2% |
| Q3 2019 | $2,343,000 | -35.2% | 151,049 | -28.2% | 0.01% | -31.6% |
| Q2 2019 | $3,613,000 | -17.6% | 210,314 | -22.8% | 0.02% | -20.8% |
| Q1 2019 | $4,385,000 | +8.8% | 272,339 | -1.1% | 0.02% | -4.0% |
| Q4 2018 | $4,029,000 | -5.6% | 275,389 | +17.2% | 0.02% | +13.6% |
| Q3 2018 | $4,269,000 | +229.9% | 234,954 | +206.3% | 0.02% | +214.3% |
| Q2 2018 | $1,294,000 | -18.6% | 76,714 | -5.5% | 0.01% | -22.2% |
| Q1 2018 | $1,590,000 | +46.4% | 81,154 | +51.5% | 0.01% | +50.0% |
| Q4 2017 | $1,086,000 | +378.4% | 53,584 | +310.6% | 0.01% | +500.0% |
| Q3 2017 | $227,000 | -32.6% | 13,050 | -41.9% | 0.00% | -75.0% |
| Q4 2013 | $337,000 | +14.2% | 22,450 | -16.0% | 0.00% | 0.0% |
| Q3 2013 | $295,000 | – | 26,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |